• In January 2026, Halozyme Therapeutics raised its 2026 total revenue guidance to a range of US$1.71 billion to US$1.81 billion, up from its prior outlook of US$1.43 billion to US$1.53 billion, and also projected 2025 revenue of about US$1.39 billion with mid‑thirties percentage year-on-year growth.
• This guidance update highlights how demand for Halozyme’s ENHANZE-enabled subcutaneous delivery partnerships is feeding through into higher expected top-line scale and cash generation.
• Next, we’ll examine how this higher 2026 revenue outlook influences Halozyme’s investment narrative, particularly around the scalability of ENHANZE.

AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Halozyme Therapeutics' Investment Narrative?

To own Halozyme, you need to believe ENHANZE can keep attracting blockbuster partners, convert that into durable royalty streams, and that management will keep translating those royalties into strong free cash flow and disciplined capital returns. The sharp step-up in 2025 and 2026 revenue guidance, on top of recent ENTYVIO and other collaborations, reinforces ENHANZE’s scalability as a near-term catalyst and helps explain the strong share price run in recent months. At the same time, the higher outlook raises the bar: execution risk around partners’ subcutaneous launches, Halozyme’s high leverage and any slowdown in royalty momentum now matter more to the story than they did before this update. For current and prospective shareholders, this guidance reset is central to both the upside case and the main risks.

However, one key risk around Halozyme’s debt profile is easy to underestimate. Halozyme Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Eight fair value estimates from the Simply Wall St Community span roughly US$77 to over US$209 per share, reflecting very different expectations. Set against Halozyme’s sharply higher revenue guidance, this spread underlines why you may want to weigh both ENHANZE’s growth potential and the balance sheet risks before deciding where you stand.

Explore 8 other fair value estimates on Halozyme Therapeutics - why the stock might be worth just $77.12!

Build Your Own Halozyme Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Halozyme Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Halozyme Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Halozyme Therapeutics' overall financial health at a glance.

Interested In Other Possibilities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.